Wednesday, July 30, 2014

Journal Spotlight: How to Treat Non-Invasive Bladder Cancer

Approximately 60k new patients are diagnosed with bladder each year in the United States.[1]  Most of those cancers (upwards of 70-80%) are non-muscle invasive urothelial cancers of the bladder (NMIUC) - meaning these are cancers that arise from the lining of the bladder and grow outward into the lumen of the bladder.[2,3] Fortunately, most of these cancers are not inherently dangerous and can be safely managed with close surveillance and a variety of interventions.  However, NMIUC represent a wide variety of tumor types and has a wide range of prognoses and therapeutic options.  Most NMIUC are treated with a combination of surgical resection (or transurethral resection of bladder tumor, TURBT) and intravesical treatment (BCG is the most common).

The American Urological Association and other groups have attempted to stratify NMIUC patients based on their risk of recurrence, progression to muscle-invasive disease and effective treatment options.  Low- and high-risk groups are well agreed upon by a number of professional urologic and oncologic organizations. However, the risk of progression and treatment options are not well flushed out in the intermediate-risk group.  A recent publication by the International Bladder Cancer Group (IBCG), in the Journal of Urology, creates a framework for intermediate-risk patients.[4]

This blog will put this manuscript in a Journal Spotlight and review the suggested definitions and treatments for patients with low-, intermediate- and high-risk NMIUC.  For more details regarding the methodology and evidence behind these conclusions, you can access the manuscript by clicking on the subsequent link:
Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J.  Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer.  J Urol. 2014 Aug;192(2):305-315. Review.

Non-muscle Invasive Urothelial Cancers of the Bladder (NMIUC)


Definition: Solitary, primary low-grade papillary Ta tumor
Well-agreed upon definition
Treatment Options:
Transurethral Resection of Bladder Tumor (TURBT)
Single, immediate post-operative chemotherapy (mitomycin C) - [Evidence: 5,6]
Office Fulguration
Active surveillance with serial cystoscopy
Cancer Outcomes:
Recurrence: 50-70%
Progression:  5-10%
Deaths: 1-5%


Definition: Multiple or recurrent low-grade Ta tumors***

The following risk factors stratify intermediate-risk patients:
  • Multiple tumors
  • Tumor size >3cm
  • Early recurrence (<1 year)
  • Frequent recurrences (>1 per year)
Those patients with no risk factors should be considered as Low-Risk NMIUC (see above).
Those patients with 1-2 risk factors should be considered as Intermediate-Risk NMIUC.
Those patients with 3 or more risk factors should be considered High-Risk NMIUC (see below).
***Not well-agreed upon definition (recently proposed by the IBCG)

Treatment Options:
Transurethral Resection of Bladder Tumor (TURBT)
Adjuvant intravesical treatment (BCG with maintenance for at least 1 year > chemotherapy)
     If recurrence while receiving chemotherapy, consider BCG induction and maintenance
     If recurrence while receiving BCG, consider maintenance therapy or alternative chemotherapy
Cancer Outcomes: [3,7]
Recurrence: 78%
Progression:  17%
Deaths: 10-25%

Evidence: A number of well-organized studies and meta-analyses demonstrate improvement in recurrence rates and other oncologic parameters for patients with intermediate-risk NMIUC receiving intravesical treatments.  BCG is superior to chemotherapeutic agents (epirubicin, mitomycin c) with regard to recurrence in nearly all studies, however progression and survival rates are often indeterminate.  Some of the important studies are highlighted:

  • Meta-analysis: reduced recurrence rates for BCG maintenance > mitomycin C, no difference in progression or death between groups. [8]
  • EORTC30911: Time to recurrence, time to distant metastases, disease-specific and overall survival improved with BCG > Epirubicin.[9]
  • FinnBladder I: reduced recurrence rate with BCG maintenance > mitomycin C; trend toward decreased progression and death rates with BCG.[10]
  • EORTC30962: full-dose BCG for 1 year associated with the best outcomes [11]


Definition: Any T1 or high-grade tumor, and/or carcinoma in situ
Well-agreed upon definition
Treatment Options:
Transurethral Resection of Bladder Tumor (TURBT)
BCG maintenance
Consider early cystectomy
Cancer Outcomes:
Recurrence: >80%
Progression:  50% within 3 years
Deaths: 33%

While this journal article highlights a deficiency in our understanding of bladder cancer and offers a framework to better classify and treat patients, it should be clearly stated that this is not standard of care nor is it an endorsement from the Brady Urological Institute. This is merely a blog where we share important work from other contributors in the field.

[1] American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
[2] Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD et al: Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083.
[3] Jones SJ and Larchian WA.  Non–Muscle-Invasive Bladder Cancer (Ta, T1, and CIS). In: Campbell-Walsh Urology, 10th ed. Edited by AJ Wein, LR Kavoussi, AC Novick, AW Partin, CA Peters. Philadelphia: W. B. Saunders 2012; chapt 81, pp 2335-54.
[4] Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J.  Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer.  J Urol. 2014 Aug;192(2):305-315. doi: 10.1016/j.juro.2014.02.2573. Epub 2014 Mar 25. Review.
[5] Gudjónsson, S., Adell, L., Merdasa, F. et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009; 55: 773
[6] Dobruch, J. and Herr, H. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?. BJU Int. 2009; 104: 170
[7] Sylvester, R.J., van der Meijden, A.P., Oosterlinck, W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466
[8] Malmström, P.U., Sylvester, R.J., Crawford, D.E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56: 247
[9] Sylvester, R.J., Brausi, M.A., Kirkels, W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57: 766
[10] Jӓrvinen, R., Kaasinen, E., Sankila, A. et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009; 56: 260
[11] Oddens, J., Brausi, M., Sylvester, R. et al. Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013; 63: 462


  1. Thanks for sharing the information about the How to Treat Non-Invasive Bladder Cancer.
    Impotency solution ,premature ejaculation treatment,solution to erection problem

  2. I would be very thankful if you continue with quality what you are serving right now with your blog. I really enjoyed it. and i really appreciate to you for this. Multi Speciality in Dombivali || Physician and Neurosurgeon in Dombivali || Multispeciality Hospitals in Dombivli

  3. I like the valuable information you provide in your blog. I will bookmark your blog and check again here frequently. I'm quite certain I will learn many new stuff right here! Best of luck for the next! Cancer Surgeon in Dombivli || Urology Center in dombivli || Orthopedic Surgeon in Dombivli

  4. i was just read your blog that was really superb got much pleasure to read that post. please keep sharing post like that.thanks for share with us for this post. Critical Care in Dombivali || Plastic Surgeon in dombivli || Orthopedic Hospital in Dombivli

  5. Very informative and impressive post you have written, this is quite interesting and i have went through it completely, an upgraded information is shared, keep sharing such valuable information. Hospitals in Dombivli || Physiotherapy in Dombivli || Hospital in Dombivli

  6. Thanks for featuring Bladder Cancer in your blog - it has been overlooked for far too long! Keep the info coming! Thanks!

  7. WHAT A GREAT MIRACLE THAT I HAVE EVER SEE IN MY LIFE. My names are Clara David I’m a citizen of USA, My younger sister was sicking of
    breast cancer and her name is Sandra David I and my family have taking her
    to all kind of hospital in USA still yet no good result. I decided to go to
    the internet and search for cancer cure so that was how I find a lady
    called peter Lizzy she was testifies to the world about the goodness of a
    herbal man who has the roots and herbs to cure all kind of disease and the
    herbal man email was there. So I decided to contact the herbal man @herbalist_sakura for my younger sister help to cure her breast cancer. I contacted him and told him
    my problem he told me that I should not worry that my sister cancer will be
    cure, he told me that there is a medicine that he is going to give me that
    I will cook it and give it to my sister to drink for one week, so I ask how
    can I receive the cure that I am in USA, he told me
    That I will pay for the delivery service. The courier service can
    transport it to me so he told me the amount I will pay, so my dad paid for
    the delivery fee. two days later I receive the cure from the courier
    service so I used it as the herbal man instructed me to, before the week
    complete my sister cancer was healed and it was like a dream to me not
    knowing that it was physical I and my family were very happy about the
    miracle of Doctor so my dad wanted to pay him 5 million us dollars the
    herbal man did not accept the offer from my dad, but I don't know why he
    didn't accept the offer, he only say that I should tell the world about him
    and his miracle he perform so am now here to tell the world about him if
    you or your relative is having any kind of disease that you can't get from
    the hospital please contact or whats app him
    +2348110114739  you can follow him up on Instagram @herbalist_sakura for the cure, he will help you out with the
    problem. And if you need more information about the doctor you can mail me